Itacitinib is now in ongoing trials for metastatic solid tumors in combination with pembrolizumab (NCT02646748); NSCLC with Osimertinib (NCT02917993); and, BRAF-mutant melanoma with small-molecule MEK and BRAF inhibitors (NCT03272464), with outcomes yet to be reported. This evidence concerns the gene BRAF and non-small cell lung carcinoma.